Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence

Colorectal Disease

Volumn 15, Issue 5, 2013, Pages 569-574

  La Torre, F ^a   de la Portilla, F ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Bulking agent; Dextranomer; Faecal incontinence; Solesta

Indexed keywords

ATROPINE PLUS DIPHENOXYLATE; DEXTRANOMER; FLEET ENEMA; HYALURONIC ACID; LOPERAMIDE; MICROSPHERE; SOLESTA; UNCLASSIFIED DRUG;

ABSCESS; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FECES INCONTINENCE; FEMALE; FEVER; FOLLOW UP; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIANAL ABSCESS; PRIORITY JOURNAL; PROCTALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTOVAGINAL SEPTUM ABSCESS; RECTUM ABSCESS; RECTUM DISEASE; RECTUM HEMORRHAGE; RECTUM PROLAPSE;

AGED; DEXTRANS; FECAL INCONTINENCE; FEMALE; FEVER; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE; RECTUM; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84877004288     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12155     Document Type: Article

References (31)

1. Oliveira L, Wexner SD. (1998). Anal incontinence. In: Fundamentals of Anorectal Surgery, 2nd edition (eds Beck DE, Wexner SD), p 557. W.B. Saunders, London, UK.
2. Kalantar JS, Howell S, Talley NJ. Prevalence of faecal incontinence and associated risk factors: an underdiagnosed problem in the Australian community? Med J Aust 2002; 176: 54-7.
3. Ho YH, Muller R, Veitch C, Rane A, Durrheim D. Faecal incontinence: an unrecognised epidemic in rural North Queensland? Results of a hospital-based outpatient study. Aust J Rural Health 2005; 13: 28-34.
4. Siproudhis L, Pigot F, Godeberge P, Damon H, Soudan D, Bigard MA. Defecation disorders: a French population survey. Dis Colon Rectum 2006; 49: 219-27.
5. Nelson R, Norton N, Cautley E, Furner S. Community-based prevalence of anal incontinence. J Am Med Assoc 1995; 274: 559-61.
6. Perry S, Shaw C, McGrother C etal. Prevalence of faecal incontinence in adults aged 40 years or more living in the community. Gut 2002; 50: 480-4.
7. Enck P, Bielefeldt K, Rathmann W, Purrmann J, Tschope D, Erckenbrecht JF. Epidemiology of faecal incontinence in selected patient groups. Int J Colorectal Dis 1991; 6: 143-6.
8. Faltin DL, Sangalli MR, Curtin F, Morabia A, Weil A. Prevalence of anal incontinence and other anorectal symptoms in women. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12: 117-21.
9. Tariq SH, Morley JE, Prather CM. Fecal incontinence in the elderly patient. Am J Med 2003; 115: 217-27.
10. Zetterström J, Mellgren A, Jensen LL etal. Effect of delivery on anal sphincter morphology and function. Dis Colon Rectum 1999; 42: 1253-60.
11. Abramowitz L, Sobhani I, Ganansia R etal. Are sphincter defects the cause of anal incontinence after vaginal delivery? Results of a prospective study. Dis Colon Rectum 2000; 43: 590-8.
12. Sato T, Konishi F, Minakami H etal. Pelvic floor disturbance after childbirth: vaginal delivery damages the upper levels of sphincter innervation. Dis Colon Rectum 2001; 44: 1155-61.
13. Bartlett L, Nowak M, Ho YH. Impact of fecal incontinence on quality of life. World J Gastroenterol 2009; 15: 3276-82.
14. Rosen HR. Modern concepts for the treatment of fecal incontinence. Acta Chir Lugosl 2002; 49: 23-4.
15. Altomare DF, La Torre F, Rinaldi M, Binda GA, Pescatori M. Carbon-coated microbeads anal injection in outpatient treatment of minor fecal incontinence. Dis Colon Rectum 2008; 51: 432-5.
16. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults (review). Cochrane Database Syst Rev 2010; 5: CD007959.
17. Leung FW. Treatment of fecal incontinence - review of observational studies (OS) and randomized controlled trials (RCT) related to injection of bulking agent into peri-anal tissue. J Interv Gastroenterol 2011; 1(4): 202-6.
18. Stenberg A, Larsson E, Lindholm A, Ronneus B, Stenberg A, Läckgren G. Injectable dextranomer-based implant: histopathology, volume changes and DNA-analysis. Scand J Urol Nephrol 1999; 33(6): 355-61.
19. Stenberg A, Larsson E, Läckgren G. Endoscopic treatment with dextranomer-hyaluronic acid for vesicoureteral reflux: histological findings. J Urol 2003; 169(3): 1109-13.
20. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M, the NASHA Dx study group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised sham controlled trial. Lancet 2011; 377: 997-1003.
21. Dodi G, Jongen J, de la Portilla F, Raval M, Altomare DF, Lehur PA. An open-label, noncomparative, multicenter study to evaluate efficacy and safety of NASHA/Dx gel as a bulking agent for the treatment of fecal incontinence. Gastroenterol Res Pract 2010; 2010: 467136.
22. World Medical Association Declaration of Helsinki. Ethical considerations for medical research involving human patients. JAMA 1998; 284: 3043-5.
23. World Medical Association. World Medical Association Declaration of Helsinki. Ethical considerations for medical research involving human patients. Nurs Ethics 1996; 9: 105-9.
24. World Medical Association. World Medical Association Declaration of Helsinki. Ethical considerations for medical research involving human patients. J Postgrad Med 2002; 48: 206-8.
25. World Medical Association General Assembly. World Medical Association Declaration of Helsinki. Ethical considerations for medical research involving human patients. J Int Bioethique 2004; 15: 124-9.
26. Oliveira L, Pfeifer J, Wexner SD. Physiological and clinical outcome of anterior sphincteroplasty. Br J Surg 1996; 83: 502-5.
27. Rothbarth J, Bemelman WA, Meijerink WJHJ, Stiggelbout AM, Zwinderman AH, Buyze-Westerweel ME, Delemarre JB. What is the impact of fecal incontinence on quality of life? Dis Colon Rectum 2001; 44: 67-71.
28. Rockwood TH, Church JM, Fleshman JW etal. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum 2000; 43: 9-17.
29. Danielson J, Karlbom U, Sonesson AC, Wester T, Graf W. Submucosal injection of stabilized nonanimal hyaluronic acid with dextranomer: a new treatment option for fecal incontinence. Dis Colon Rectum 2009; 52: 1101-6.
30. Guerra F, Velluti F, Crocetti D, La Torre F. PTQ™ bulking agent injection for the treatment of fecal incontinence: QoL and manometric evaluation. Pelviperineology 2010; 29: 27-9.
31. ® P100014: Center for Devices and Radiological Health (CDRH) Advisory Panel. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/medicaldevices/medicaldevicesadvisorycommittee/gastroenterologyurologydevicespanel/ucm235143.pdf (accessed December 2010).